The Hunan Healthcare Security Administration has published a list of 226 drugs to be included under the “dual channel” single-line payment management system, which includes 43 newly added products from the 2023 National Reimbursement Drug List (NRDL) negotiations. The targeted drugs are characterized by high clinical value, urgent need, and low substitutability. These drugs will be accessible through outpatient and designated retail pharmacy channels, with payments covered by both designated hospitals and pharmacies. The public comment period for the list ends on December 27, with 50 drugs removed compared to the previous year.
Under the “dual channel” management, drugs are subject to unified single-line payment policies in designated medical institutions and pharmacies. There is no payment benchmark for these expenses, and they are not subject to segmented policy payment during hospitalization. During a medical insurance settlement cycle, the insured patient’s expenses are first covered by basic medical insurance funds at a 70% reimbursement ratio for urban employees and 60% for urban and rural residents. Excess amounts are covered by mutual aid for serious illnesses among urban employees or major illness insurance for urban and rural residents, if applicable. Individual payments for “dual channel” management drugs are not covered under serious illness mutual aid or insurance. The actual reimbursement amount for these drugs is included in the annual maximum payment limit for urban employee or urban and rural resident medical insurance, with any amount exceeding this limit not paid. The “dual channel” management of drugs adheres to the limited payment range specified in the current national reimbursement drug list without a separate limit.- Flcube.com
